News
New research on using weight loss drugs for treating alcohol use disorder
Some weight loss and diabetes drugs that use GLP-1s have been found to help people stop drinking. Channel 5's GM released a statement saying the station and its parent company require employees "to adhere to the highest ethical standards.
The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas ...
However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use ...
Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...
Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with ...
By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance. Revenue hit $ ...
Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...
Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results